Navigation Links
GeneNews restructures operations
Date:11/12/2008


- North American resources focused on commercialization of

ColonSentry(TM); Asian resources focused on pipeline development and

local commercialization -

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has implemented a strategic restructuring of its North American and Asian operations. The Company's operation in Canada will focus on the Canadian and U.S. commercialization of its lead product, ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer. Research and development of the Company's pipeline, including patient sample accrual to support these activities, will be moved to GeneNews' Asian operations. As part of the restructuring, the Company has reduced its workforce in Canada by 40%.

"While these actions are difficult, when assessing the structure of our company and our strengths in Canada and Asia, we determined that there were efficiencies in research and development that could be better leveraged from our Asian operations in Penang, Malaysia and Tianjin, China," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "Transferring this segment of our operations to our Asian facilities also enhances opportunities to access to capital from Asian sources, which GeneNews has successfully secured in the past, to support research and development activities including the accrual of patient samples to support our pipeline development. We will also be better positioned to attract resources and expertise to facilitate the commercial launch of our products in China, Malaysia and the surrounding regions."

Dr. Dreismann continued: "This restructuring will result in a substantial reduction in cash expenditures in Canada over the near term and allows us to completely refocus our North American sources on the commercialization of our lead ColonSentry(TM) product in Canada and the U.S. As we roll out our test in additional regions in Canada and prepare for its commercial launch in the U.S. in the second half of 2009, we believe that a leaner and more focused organization will provide a significant strategic advantage to GeneNews."

The Company will maintain its global headquarters in Canada where it will focus on Canadian marketing activities and development of a U.S. marketing and reimbursement strategy for the ColonSentry(TM) test. GeneNews will continue development and validation of the ColonSentry(TM) test to support a CLIA submission and the operation of a centralized clinical reference laboratory to serve the North American market from its global headquarters. Scientific leadership and direction for research and development activities that will be pursued by the Company's Asian facilities and the development of a strategy to create a personalized health management system based on the Sentinel Principle(TM) will also be managed in the Company's global headquarters.

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
2. GeneNews Announces Second Quarter Results
3. GeneNews launches worlds first blood test for colorectal cancer screening
4. GeneNews announces management changes to support commercialization of ColonSentry(TM)
5. Genenews adds two members to its Board of Directors
6. GeneNews Announces First Quarter Results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews announces 2007 year end results
9. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
10. GeneNews receives ISO 13485 accreditation
11. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):